Visudyne sustains vision benefit after three years:
This article was originally published in Clinica
Executive Summary
QLT and Novartis say that three-year follow-up data is now available to support their photodynamic therapy for age-related macular degeneration, the leading cause of blindness in people over the age of 50. The average visual acuity of patients who received the therapy, Visudyne, remained stable between the 24th and 36th month of follow-up, while the number of Visudyne treatments required continued to decrease, says QLT, of Vancouver, British Columbia. All the patients studied had predominantly classic subfoveal choroidal neovascularisation - the indication for which Visudyne is currently approved in the US and Europe.